Below is our recent interview with Nick Campbell, Chief Revenue Officer at Anju Software:
Q: Could you provide our readers with a brief introduction to your organization?
A: Anju Software provides adaptive technology solutions for clinical trials and medical affairs and a newly designed, state-of-the-art clinical content and data repository. It’s an AI-based analytical solution combined with data and application integration capabilities, serving the worldwide pharmaceutical, biotech and contract research Life Sciences markets.
Q: Any highlights on your recent announcement?
A: TrialMaster 5.1 addresses some of the most time-consuming challenges of biopharma companies in building clinical studies and rolling out drug trials. It has a range of enhanced trial efficiency capabilities, highlighted by a unique company-created technology called Parameterized Edit Check that facilitates reuse of edit checks for flagging inaccurate data across multiple clinical trials.
Q: Can you give us more insights into your offering?
A: While technologies exist for automating the edit check process on a trial-to-trial basis, there has previously never been a clinical trial management software application that could combine edit check functionality for the more standard data categories found across trials with data variables found in specific trials, thereby easing reuse in any trial implementation. Parameterized Edit Check technology allows edit checks to be written once and used over and over again in future trials.
Supported over any desktop, laptop, tablet, or smartphone device, TrialMaster 5.1 is a complete EDC system that makes it easier for clinical professionals to collect and manage their study data, thereby decreasing preparation time before a clinical trial goes live and freeing up additional time to monitor patient responses once a trial is live.
The combination of reduced study build time, better trial insight, and more efficiency improvements throughout the study lifecycle offered by TrialMaster 5.1 allows biopharmaceutical organizations to focus on developing new treatments and accelerating their time to market to make an impact on patient lives.
Q: What can we expect from your company in next 6 months? What are your plans?
A: Anju will continue to develop innovative software and technology solutions that deliver faster answers through better insights for the global life sciences and biopharmaceutical industry. Anju is committed to responding to and staying ahead of the challenges that could impact the development, commercialization and healthcare stakeholder understanding of critical drugs and treatments for patients that need them, and supporting the industry professionals involved in bringing therapies to market by equipping them with technology tools that streamline, enhance and optimize efficiencies in their work processes. We will look for opportunities to collaborate with clients, manufacturers and healthcare system influential voices to knowledge-share and develop new approaches for simplifying an increasingly complex life sciences industry triggered by an overwhelming explosion of clinical and medical data.
Q: What is the best thing about your company that people might not know about?
A: Our technology has accelerated the development and market adoption of a number of COVID-19 vaccines and treatments and we work with 16 of the top 20 biopharmaceutical companies in the world.